Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 370 versus GADOTERATE MEGLUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 370 versus GADOTERATE MEGLUMINE.
ANGIOVIST 370 vs GADOTERATE MEGLUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 370 (diatrizoate meglumine) is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of vascular structures and organs during imaging procedures.
Gadoterate meglumine is a paramagnetic contrast agent that increases the relaxation rate of water protons in tissues, thereby enhancing image contrast in magnetic resonance imaging (MRI). It is a macrocyclic gadolinium-based contrast agent (GBCA) with high thermodynamic stability and kinetic inertness, reducing the risk of gadolinium dissociation.
Intravenous injection: 1-2 mL/kg (370 mg I/mL) up to 150 mL total for CT imaging; intra-arterial injection: 5-80 mL depending on procedure. Rate: 1-5 mL/sec.
0.2 mL/kg (0.1 mmol/kg) intravenously as a single bolus injection.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life approximately 1.5–2 hours in patients with normal renal function; prolonged in renal impairment (up to 12–34 hours in severe impairment).
Primarily renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours, with less than 1% biliary/fecal.
Primarily renal (99% excreted unchanged in urine within 24 hours); biliary/fecal elimination negligible (<1%).
Category C
Category C
Contrast Agent
Contrast Agent